The objective of the study was to evaluate the role of omega-3 polyunsaturated fatty acids (PUFAs) in preventing of atrial fibrillation (AF) recurrence. The study included 75 patients (49 men and 26 women, mean age 57.2±7.4 years) with moderate hypertension and stable coronary heart disease who had a history of paroxysmal AF and sinus rhythm at the start of the study. Patients were divided into two groups: 1st group (n=43) consisted of patients who received only standard therapy within 6 months, in the 2nd group (n=32) the encapsulated highly purified long-chain omega-3 PUFA 1 g/day were added. The number and duration of atrial fibrillation recurrences, dosage of propafenone and time required to restore sinus rhythm and frequency of arrhythmogenic hemodynamic disorders were estimated. During follow-up period AF recurrences were recorded in 20 (49 %) patients in 1st group and only in 6 (20 %) of the 2nd group (X2=5.00; Р=0.025). The decrease of absolute risk of AF recurrent in patients receiving omega-3 PUFA was 29 % (confidence interval 6.2–46.9 %, Р=0,05). There was significantly fewer (Р<0.05) number of AF paroxysms per patient and greater number of episodes with spontaneous restoration of sinus rhythm in the 2nd group compared with the 1st. In group 2 there was a more
rapid restoration of sinus rhythm with less dosage of propafenone required. The incidence of hemodynamic disorders during AF paroxysm was also significantly lower in the 2nd group. In conclusion, omega-3 PUFAs
added to standard therapy in patients with coronary artery disease and hypertension for 6 months reduced the risk of AF recurrence by 29 %.